Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2) - 07/06/26
on behalf of the
SLIM-2 study group
ABSTRACT |
Background |
The periprocedural management of elective invasive coronary angiography (ICA) or percutaneous coronary intervention (PCI) of patients using direct oral anticoagulation (DOAC) remains debated. This trial aims to evaluate whether continuing DOAC therapy is as safe as temporary interruption, by comparing in-hospital and 30-day bleeding and ischemic outcomes.
Methods |
The South Limburg Myocardial Infarction 2 (SLIM-2) trial (NCT04977076) is an investigator-initiated, multicenter, randomized controlled trial. A total of 1,270 patients using DOAC and scheduled for elective ICA or PCI will be randomized in a 1:1 ratio to uninterrupted or interrupted therapy. The primary endpoint is in-hospital bleeding, classified as type 2, 3, or 5 according to the Bleeding Academic Research Consortium (BARC). Secondary endpoints are 30-day bleedings, major adverse cardiac and cerebrovascular events (MACCE), and net adverse clinical events (NACE, MACCE plus bleeding events).
Conclusion |
The SLIM-2 trial is the first large-scale randomized controlled trial to evaluate the safety of uninterrupted DOAC therapy in elective ICA and PCI. Its results will provide critical evidence to guide periprocedural anticoagulation management and may inform future clinical practice guidelines.
Trial Registration |
The trial is registered at clinicaltrials.gov/ with the number NCT04977076?cond=NCT04977076&viewType=Card&rank=1 . NCT04977076?term=NCT04977076&viewType=Card&rank=1
Le texte complet de cet article est disponible en PDF.Plan
Vol 299
Article 107462- septembre 2026 Retour au numéro
Article précédent
- Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial
- Anne Sophie Overgaard Olesen, Jasmin Dam Lukoschewitz, Ida Arentz Taraldsen, Ahmed Najim, Nora Olsen El Caidi, Simone Bonde Haastrup, Sandra Tonning, Rasmus Gregersen Mottlau, Hanne Nygaard, Brett Doleman, Søren Junge Nielsen, Jakob Hartvig Thomsen, Jens Dahlgaard Hove, Ekim Seven, Fredrik Folke, Matias Greve Lindholm, Janus Christian Jakobsen, Jens Jakob Thune, Johannes Grand
- CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics
- Jeffrey L. Anderson, Heidi T. May, Tyler Winslow, Viet T. Le, Leslie Iverson, Tami L. Bair, Kirk U. Knowlton, Joseph B. Muhlestein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?